BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 21969911)

  • 1. Lambert-eaton myasthenic syndrome; pathogenesis, diagnosis, and therapy.
    Gilhus NE
    Autoimmune Dis; 2011; 2011():973808. PubMed ID: 21969911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lambert-Eaton myasthenic syndrome - diagnosis, pathogenesis and therapy.
    Hülsbrink R; Hashemolhosseini S
    Clin Neurophysiol; 2014 Dec; 125(12):2328-36. PubMed ID: 25065299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.
    Schoser B; Eymard B; Datt J; Mantegazza R
    J Neurol; 2017 Sep; 264(9):1854-1863. PubMed ID: 28608304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [P/Q-type Calcium Channel Antibodies in Lambert-Eaton Myasthenic Syndrome].
    Kitanosono H; Shiraishi H; Motomura M
    Brain Nerve; 2018 Apr; 70(4):341-355. PubMed ID: 29632282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Autoantibody against the presynaptic P/Q-type voltage-gated calcium channel in Lambert-Eaton myasthenic syndrome].
    Sakai W; Nakane S; Matsuo H
    Brain Nerve; 2013 Apr; 65(4):441-8. PubMed ID: 23568992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoimmunity to the voltage-gated calcium channel underlies the Lambert-Eaton myasthenic syndrome, a paraneoplastic disorder.
    Vincent A; Lang B; Newsom-Davis J
    Trends Neurosci; 1989 Dec; 12(12):496-502. PubMed ID: 2480664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GRP78 antibodies damage the blood-brain barrier and relate to cerebellar degeneration in Lambert-Eaton myasthenic syndrome.
    Shimizu F; Takeshita Y; Sano Y; Hamamoto Y; Shiraishi H; Sato T; Yoshimura S; Maeda T; Fujikawa S; Nishihara H; Kitanosono H; Tsujino A; Motomura M; Kanda T
    Brain; 2019 Aug; 142(8):2253-2264. PubMed ID: 31236596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Lambert-Eaton myasthenic syndrome].
    Motomura M; Fukuda T
    Brain Nerve; 2011 Jul; 63(7):745-54. PubMed ID: 21747145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lambert-Eaton myasthenic syndrome.
    Lipka AF; Verschuuren JJGM
    Handb Clin Neurol; 2024; 200():307-325. PubMed ID: 38494285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lambert-Eaton Myasthenic Syndrome.
    Kesner VG; Oh SJ; Dimachkie MM; Barohn RJ
    Neurol Clin; 2018 May; 36(2):379-394. PubMed ID: 29655456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Lambert-Eaton Myasthenic Syndrome].
    Matsuo H
    Brain Nerve; 2024 May; 76(5):630-634. PubMed ID: 38741506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simulations of active zone structure and function at mammalian NMJs predict that loss of calcium channels alone is not sufficient to replicate LEMS effects.
    Ginebaugh SP; Badawi Y; Laghaei R; Mersky G; Wallace CJ; Tarr TB; Kaufhold C; Reddel S; Meriney SD
    J Neurophysiol; 2023 May; 129(5):1259-1277. PubMed ID: 37073966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Voltage gated calcium channel antibody-related neurological diseases.
    Bekircan-Kurt CE; Derle Çiftçi E; Kurne AT; Anlar B
    World J Clin Cases; 2015 Mar; 3(3):293-300. PubMed ID: 25789302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies.
    Titulaer MJ; Lang B; Verschuuren JJ
    Lancet Neurol; 2011 Dec; 10(12):1098-107. PubMed ID: 22094130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ca2+ channels as targets of neurological disease: Lambert-Eaton Syndrome and other Ca2+ channelopathies.
    Flink MT; Atchison WD
    J Bioenerg Biomembr; 2003 Dec; 35(6):697-718. PubMed ID: 15000529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lambert-eaton myasthenic syndrome differential reactivity of tumor versus non-tumor patients to subunits of the voltage-gated calcium channel.
    Pellkofer HL; Armbruster L; Krumbholz M; Titulaer MJ; Verschuuren JJ; Schumm F; Voltz R
    J Neuroimmunol; 2008 Nov; 204(1-2):136-9. PubMed ID: 18809213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Lambert-Eaton myasthenic syndrome, an immune pathology of neuromuscular junctions].
    Honnorat J
    Bull Acad Natl Med; 2014 Feb; 198(2):243-54; discussion 255. PubMed ID: 26263702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Lambert-Eaton myasthenic syndrome: diagnosis and treatment].
    Motomura M; Iwanaga H
    Clin Calcium; 2001 Nov; 11(11):1468-74. PubMed ID: 15775666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lambert-Eaton myasthenic syndrome: search for alternative autoimmune targets and possible compensatory mechanisms based on presynaptic calcium homeostasis.
    Takamori M
    J Neuroimmunol; 2008 Sep; 201-202():145-52. PubMed ID: 18653248
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.